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Ceftriaxone (CFTX) sodium is a third-generation, broad-spectrum cephalosporin that is resistant to beta-
lactamases. An alternative bioassay for the assessment of the potency of this drug in pharmaceutical 
formulations has not been previously reported. Thus, this paper reports the development and full validation 
of a 3 x 3 agar diffusion bioassay using a cylinder-plate method to quantify CFTX sodium in pharmaceutical 
samples. The strain Staphylococcus aureus ATCC 6538P was used as the test microorganism, and the 
results of the proposed bioassay displayed high linearity, precision, accuracy, specificity and robustness. 
All potency results were statistically analyzed using an analysis of variance (ANOVA) and were found to 
be linear (r=0.99999) in the range of 16–64 μg/mL, accurate (100.5%), and precise [repeatability: relative 
standard deviation (RSD)=1.4%; intermediate precision: between-day RSD=2.1% and between-analyst 
RSD=2.5%]. The specificity of the bioassay was determined by evaluating a degraded sample (50 ºC) at 
0, 24 and 48 hours as compared against the results from the pharmacopeial liquid chromatography method 
for CFTX. The results validated the proposed microbiological assay, which allows reliable quantitation 
of CFTX in pharmaceutical samples. Moreover, it is a useful, simple and low-cost alternative method 
for monitoring the quality of this medicine.
Uniterms: Ceftriaxone/agar diffusion assay. Ceftriaxone/quality control. Ceftriaxone/microbiological 
assay. Drugs/quality control.
A ceftriaxona sódica é uma cefalosporina de terceira geração de uso parenteral, com amplo espectro 
de atividade e resistente a b-lactamases. Este estudo apresenta o desenvolvimento e validação de um 
bioensaio por difusão em ágar usando o método de cilindros em placas para determinação da potência 
deste antibiótico. A validação desenvolvida apresentou bons resultados em termos de linearidade, 
precisão, exatidão, especificidade e robustez. Empregou-se o Staphylococcus aureus ATCC 6538P como 
micro-organismo teste. Os resultados dos ensaios foram tratados estatisticamente utilizando-se análise 
de variância (ANOVA). O método apresentou linearidade (r=0,99999) na faixa de doses selecionada 
(16-64 µg/mL), precisão (repetibilidade: DPR=1,4%; precisão intermediária: inter-dias DPR=2,1% e 
inter-analistas: DPR=2,5%) e exatidão de 100,5%. A especificidade do bioensaio foi avaliada através da 
análise comparativa, por cromatografia líquida de alta eficiência, de amostras degradadas a 50 ºC nos 
tempos zero, 24 e 48 h. Os resultados encontrados demonstraram a validade do bioensaio proposto, o 
qual permite a quantificação confiável de ceftriaxona sódica em produtos farmacêuticos comerciais. Por 
ser metodologia simples e de baixo custo constitui-se em alternativa para a análise de rotina do controle 
de qualidade de medicamentos.
Unitermos: Ceftriaxona/ensaio de difusão em ágar. Ceftriaxona/controle de qualidade. Ceftriaxona/
ensaio microbiológico. Fármacos/controle de qualidade.
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INTRODUCTION
Ceftriaxone (CFTX) sodium is a semisynthetic 
antibiotic that can effectively treat several types of 
bacterial infections. Unlike the other 3rd generation 
cephalosporins, CFTX has a long plasma half-life, up to 
4- to 10-times longer than the other antibiotics in this class 
(Neu et al., 1981; Stoeckel, 1981). This cephalosporin 
shows a broad spectrum against Gram-positive and Gram-
negative bacteria, including enterobacteria, Haemophilus 
influenzae and Streptococcus pneumoniae (Rebuelto et 
al., 2002).
Regarding the official quality control of CFTX, 
as raw material or in pharmaceutical preparation, the 
pharmacopeias recommend employing reversed phase 
liquid chromatography (RP-HPLC) with UV detection 
and a mobile phase composed of water, phosphate buffer 
and acetonitrile (British Pharmacopoeia, 2009; European 
Pharmacopoeia, 2005; Japanese Pharmacopeia, 2006; 
United States Pharmacopeia, 2011).
Several alternative physicochemical methods 
to assay CFTX in pharmaceutical formulations are 
described in the literature, such as spectrophotometric 
methods (El-Walily et al., 2000; Al-Momani, 2001; 
Amim, Ragab, 2004; Sankar et al., 2006; Okoye et al., 
2007; Adegoke, Quadri, 2012), flow injection analysis 
(FIA) with chemiluminescence detection (Yinhuan, 
Jiuru, 2006), spectrofluorometry (Shah et al., 2011), 
reversed-phase high-performance liquid chromatography 
(RP-HPLC) (Hecq et al., 2006; Jane et al., 2006; Tippa, 
Singh, 2010; Akl et al., 2011), high performance thin layer 
chromatography (HPTLC) (Eric-Jovanovic et al., 1998) 
and differential pulse polarography (DPP) (Sengün et al., 
1985).
To assess the concentration of CFTX in biological 
matrices such as plasma, serum, cerebrospinal fluid 
and bile, several physicochemical methods have been 
reported, such as HPLC (Patel et al., 1981; Trautmann, 
Haefelfinger, 1981; Ascalone, Dal Bò, 1983; Bowman 
et al., 1984; Chan et al., 1986; Granich, Krogstad, 1987; 
Bompadre et al., 1998; Kohlhepp et al., 1998; Tsai et al., 
1999; Nemutlu et al., 2009; Mcwhinney et al., 2010), 
spectrofluorometric assays (Omar et al., 2009), and 
capillary zone electrophoresis (CZE) (Quaglia et al., 
1997). Microbiological techniques are used to evaluate the 
bioavailability of CFTX in biological fluids (Rebuelto et 
al., 2002; Ismail et al., 2005) and to study the susceptibility 
of several microorganisms to CFTX (Beskid et al., 1981; 
Eickhoff, Ehret, 1981; Baumgartner, Glauser, 1983; 
Emmerson et al., 1985; Dias et al., 1998).
The use of microbiological assays to evaluate the 
potency of CFTX in pharmaceutical formulations is 
uncommon. The literature reports only one method which 
uses a 5 point calibration curve with paper discs in a bi-
layer agar diffusion assay using Bacillus subtilis (ATCC 
6633) as the test microorganism (Cantón et al., 1993). 
However, the original method was not validated and the 
quantification does not follow the procedure recommended 
for a 5 x 1 assay (Esteban et al., 1990).
Physicochemical techniques are recognized to be 
fast, precise and accurate in quantifying cephalosporin 
antibiotics. However, some disadvantages are inherent 
to these methods, as the interference of the excipients, 
tedious extraction steps and lack of selectivity complicate 
the performance (Ahmed et al., 2011; Adegoke et al., 
2012). Furthermore, most of these procedures are not 
simple in the routine analyses, they require dedicated or 
sophisticated equipment and expensive reagents, which 
are often not available in quality control laboratories (El-
Walily et al., 2000; Souza et al., 2006).
Alternative methods to evaluate the potency of 
antibiotics, such as the fully validated microbiological agar 
diffusion assay, are simple and operationally inexpensive. 
Furthermore, such bioassays are suitable for quality 
control laboratories that do not have specialized and 
sophisticated instruments (Souza et al., 2006; Schmidt et 
al., 2008,2009).
Therefore, the aim of the present study was to 
develop and validate a low-cost, simple, specific, accurate 
and reproducible microbiological agar diffusion assay 
using a cylinder-plate method and propose it as a useful 
alternative to the physicochemical methods described in 
the literature for quantitation of ceftriaxone sodium as raw 
material and injectable formulation.
MATERIAL AND METHODS
Chemicals
The ceftriaxone sodium reference standard from 
Brazilian Pharmacopeia (assigned purity 847.3 µg/mg) 
and the sample were commercially obtained. The sample 
(batch 97728B) was within its shelf-life and claimed to 
contain 500 mg of ceftriaxone sodium sterile powder 
for injection (Eurofarma, Brazil). All reagents used were 
analytical grade (Difco, USA; Merck, Germany). Ultrapure 
and bidistilled water were used in the experiments.
Ceftriaxone sodium reference solution
Ten milligrams of the ceftriaxone sodium reference 
standard was transferred into a 100 mL volumetric flask 
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and dissolved in sterile phosphate buffer solution pH 7 
[K2HPO4 1.36% (w/v) and KH2PO4 0.4% (w/v)]. Aliquots 
of this solution were diluted in the identical buffer yielding 
working solutions with final concentrations of 16, 32 and 
64 μg/mL (S1, S2 and S3, respectively).
Preparation of the sample solutions
Five-hundred milligrams of the CFTX sample was 
transferred to a 250 mL volumetric flask and dissolved 
with sterile phosphate buffer solution pH 7. Five milliliters 
of this solution were transferred to a 25 mL volumetric 
flask and dissolved to obtain a final concentration of 
400 µg/mL. Aliquots of this solution were further diluted 
in the identical buffer solution to obtain the concentrations 
of 16, 32 and 64 μg/mL (T1, T2 and T3, respectively), 
which were tested against S1, S2 and S3.
Microorganism and inoculum standardization
The strain Staphylococcus aureus ATCC 6538P 
was selected as the test microorganism because of its 
susceptibility to ceftriaxone sodium, yielding sharply 
defined zones of growth inhibition, which allows more 
precise measurements. The culture of Staphylococcus 
aureus ATCC 6538P (INCQS - National Institute for 
Health Quality Control, Brazil), after reconstitution, were 
cultivated and maintained on Grove-Randall’s 1 culture 
medium (Difco). The microorganism standardization 
was prepared according to the procedure described in 
the Brazilian and USP Pharmacopeias (Farmacopeia 
Brasileira, 2010; United States Pharmacopeia, 2011). 
Prior to use, the microorganism was grown in a slant 
medium (Grove-Randall’s 1, for 24 h at 35 ± 2 °C). Using 
aseptic techniques, the growth was suspended in a 0.9% 
NaCl sterile solution and diluted to give a suspension 
with 25 ± 2% turbidity (transmittance) at 580 nm using a 
10 mm absorption cell, with 0.9% NaCl sterile solution 
as blank. The Grove-Randall’s 1 culture medium at 48 °C 
was inoculated with the standardized suspension at 1% 
(v/v) to compose the upper layer in the plate.
Agar diffusion bioassay
The bioassay followed the 3 × 3 parallel line design 
(3 doses of standard and 3 doses of sample in each plate), 
with 6 plates/assay, in accordance with the European and 
Brazilian Pharmacopoeias (European Pharmacopoeia, 
2005; Farmacopeia Brasileira, 2010). For the base 
layer agar, 21 mL of Grove-Randall’s 2 culture medium 
(Difco) in a 100 × 20 mm Petri dish was used. After 
solidifying, 5 mL of inoculated Grove-Randall’s 1 
medium was poured onto the base layer. In each plate, 
6 stainless steel cylinders (8 × 6 × 10 mm – external 
diameter x internal diameter x height) were placed on 
the surface of the inoculated medium. Three alternated 
cylinders were filled with 150 μL of reference solutions 
(S1, S2 and S3), and the other three cylinders were 
filled with the concentrations of the sample solutions 
(T1, T2 and T3) (Figure 1). The plates were incubated 
at 35 ± 2 ºC aerobically for 16 h. The growth inhibition 
zone diameters (mm) were carefully measured with an 
electronic caliper. All experiments were performed in a 
biological safety cabinet and the infected material was 
decontaminated before being discarded.
HPLC
In addition to the bioassay, the remaining CFTX 
after hydrolysis degradation was assessed by a LC 
method using the chromatographic conditions described 
in the USP monograph for CFTX sodium (United States 
Pharmacopeia 2011). Briefly, 20 µL sample volumes were 
injected into a LC system (Shimadzu LC-10AD, Japan) 
equipped with a 270-nm detector and a C18 column (4 x 
150 mm). Each sample was run in triplicate. The mobile 
phase (water, acetonitrile, buffer solution pH 7, buffer 
solution pH 5 – 552:400:44:4) containing 0.32% of 
tetraheptylammonium bromide was used at a flow rate of 
2 mL/min.
FIGURE 1 - CFTX potency evaluation by agar diffusion assay 
using the cylinder-plate method with a 3 x 3 experimental 
design. Zones of growth inhibition observed for doses 16, 32 
and 64 μg/ml of the CFTX reference substance (S1, S2, S3) and 
sample (T1, T2, T3) using the strain S. aureus ATCC 6538P.
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Calculations
In all  experiments, the CFTX potency was 
statistically calculated using the parallel-line model for a 3 
x 3 assay design. The regression, parallelism and linearity 
of the response were evaluated by an analysis of variance 
(ANOVA). To complement the statistical validation, the 
confidence interval (IC95) of each assay was considered 
(Farmacopeia Brasileira, 2010; Hewitt, 2003; European 
Pharmacopoeia, 2005; ICH, 2005; Schmidt et al., 2009).
Validation of the method
All experimental conditions of the proposed method 
were tested and adjusted prior to the validation to ensure 
the best assay conditions. The method was validated 
according the International Conference on Harmonization 
(ICH 2005) and USP guidelines 2011). The following 
operational characteristics were evaluated:
Range – Assessed by the selected doses for the 
calibration curve and confirmed by determination of the 
accuracy, precision and linearity of the method.
Linearity – Evaluated through 12 independent assays 
using linear regression analysis and calculated by a least-
squares method for three doses of the reference substance.
Precision – Assessed through the repeatability 
and intermediate precision and expressed as the relative 
standard deviation (RSD). The repeatability was examined 
by assaying 6 different test solutions of the CFTX sample 
against the reference standard. The assays were performed 
by the same analyst, under identical experimental 
conditions in one day (intraday). The intermediate 
precision was evaluated by performing the analysis in 
the same laboratory on 2 separate days (interday) with 
different analysts (between-analysts).
Accuracy – The test was repeated in three consecutive 
days. Three concentration levels, covering 80% to 120% 
of the selected range of 16, 32 and 64 μg/mL, were 
tested each day. Forty mg of CFTX was transferred to 
a 100 mL volumetric flask and dissolved in a phosphate 
buffer solution pH 7.0 to obtain a stock solution with a 
concentration of 400 μg/mL. The 3 concentration levels 
at 100% were prepared from aliquots of 1, 2 and 4 mL of 
the stock solution transferred into 50 mL volumetric flasks 
and diluted with a phosphate buffer solution pH 7 to give 
final concentrations of 16, 32 and 64 μg/mL, respectively. 
The doses at 80% nominal concentration were prepared 
from aliquots of 0.8, 1.6 and 3.2 mL of the stock solution 
transferred into 25 mL volumetric flasks to give final 
concentrations of 12.8, 25.6 and 51.2 μg/mL, respectively. 
The doses at 120% nominal concentration were obtained 
from aliquots of 1.2, 2.4 and 4.8 mL of the stock solution 
transferred into 25 mL volumetric flasks and diluted with 
phosphate buffer solution pH 7 to give solutions with final 
concentrations of 19.2, 38.4 and 76.8 μg/mL, respectively. 
These working solutions were assayed against the 3 
concentration levels of the reference standard solution at 
100% nominal concentration.
Selectivity – The ability of the proposed method 
to assess the content of CFTX sodium in the presence 
of impurities and degraded substances was tested by 
comparing the results obtained in the bioassay to the 
results from the pharmacopeial LC method for the 
identical degraded sample. A CFTX sodium commercial 
sample was reconstituted with water for injection and 
heated to 50 ºC for 2 days. The sample was analyzed by 
both methods at 0, 24 and 48 h. The conditions of the LC 
method were in accordance with the USP monograph for 
CFTX sodium (United States Pharmacopeia, 2011).
Robustness – Several method parameters were 
modified in assaying a CFTX sample. The considered 
factors were the inoculum concentration (1.3%), 
incubation temperature (32 °C), volume of the inoculated 
layer (thickness – 4 mL) and the solvent used for the 
standard and sample dilution (sterile water for injection).
RESULTS AND DISCUSSION
The use of a suitable analytical method is fundamental 
in the quality control of active substances in either the 
pharmaceutical or raw material form. The choice of the 
method is normally based on several factors such as the 
drug source; its complexity; purity and sample quantity; and 
the qualitative, semi-quantitative or quantitative purpose 
of the method. Furthermore, the availability of equipment 
and reagents should be considered in the development of 
accessible and useful methodologies.
Taking in account that the potency of an antibiotic 
may be assessed through the comparison of the inhibition of 
growth of a susceptible microorganism induced by known 
concentrations of the antibiotic and its respective reference 
standard (European Pharmacopoeia, 2005; United States 
Pharmacopeia, 2011), a 3 x 3 microbiological assay was 
proposed for determining the CFTX sodium concentration 
in injectable pharmaceutical dosage forms.
The range of the doses selected (16 to 64 μg/mL) for 
the bioassay was shown to be most appropriate for this assay 
system for the following reasons: the susceptibility of the 
microorganism to lower concentrations on the curve, the 
linear relationship between the logarithm of the dose and the 
observed response, and the significant slope of the curve. 
The linearity study involved 12 independent assays with 
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6 plates/assay. The experimental average zone diameters 
(mm) and RSD values (%) for the standard solutions are 
presented in Table I. The difference between the average 
size of the inhibition zones for doses 16-32 µg/mL, 
and 32-64 µg/mL was approximately 3 mm, showing 
good linearity in the response obtained by the method. 
Furthermore, the RSD values showed low variability in 
the response (intradose) obtained in this bioassay.
.
The logarithm of the concentrations (μg/mL) and 
the mean diameter of the inhibition zones (mm) were used 
to calculate the calibration curve for CFTX. The method 
showed good linearity for the range of 16–64 μg/mL. 
The representative linear equation was y = 10.176x + 
4.046. The determination coefficient (r2=0.99998) and 
correlation coefficient (r=0.99999) were highly significant. 
The bioassays were validated using an analysis of variance 
(ANOVA). In all experiments, the regression was highly 
significant (P<0.05) and no deviation was found in either 
the parallelism or the linearity (P>0.05). Moreover, all 
bioassays gave potency results within a confidence interval 
of 90–115% (IC95), indicating that the experiments 
performed during the validation were well executed. 
Simultaneously, the developed method was found to have 
significant response differentiation between doses and 
significant sensitivity to the selected doses. 
The bioassay precision, in terms of repeatability 
(intra-assay), was evaluated by analyzing, on identical 
days, six different test solutions of CFTX sodium powder 
for injection with identical theoretical concentrations. 
The CFTX activity ranged from 99.2% to 102.8%, with 
an RSD value of 1.4% (Table II).
To calculate the intermediate precision, the same 
sample was analyzed in triplicate on 2 separate days 
(between-day; Table III) and by 2 different analysts 
(between-analysts; Table IV), yielding RSD values of 
2.1% and 2.5%, respectively. These low RSD values 
confirmed the capacity of the method to generate, with 
the same sample, reproducible results with a low response 
variation in independent assays.
TABLE III - Between-day precision data of the CFTX bioassay. 
Sample solutions at 100% theoretical concentration were tested 
in triplicate in two separate days
Day Potency found 
(%)
Confidence interval 
(IC95)
RSD 
(%)
1
100.5 91.9 - 109.9
2.1
101.8 95.6 - 108.5
102.8 95.4 - 110.9
2
102.8 93.0 – 113.8
99.6 96.0 – 103.3
97.5 93.2 – 101.9
TABLE IV - Between-analyst precision results obtained in the 
CFTX bioassay validation. Sample solutions at 100% theoretical 
concentration were tested in triplicate by two analysts
Analyst Potency 
found (%)
Confidence interval 
(IC95) RSD (%)
1
99.6 96.0 - 103.3
2.5
97.5 93.2 - 101.9
102.8 93.0 - 113.8
2
96.2 91.5 – 101.1
97.1 91.9 – 102.5
97.3 90.8 – 104.2
TABLE II – Results of the repeatability evaluation of the 
microbiological assay of CFTX powder for injection
Theoretical 
amount 
(mg/fa)
Experimental 
amount 
(mg/fa)
Potency 
(%)
Confidence 
interval 
(IC95)
RSD 
(%)
500
514.2 102.8 95.4 - 110.9
1.4
496.2 99.2 93.1 - 105.8
499.8 99.9 97.3 - 102.7
512.5 102.5 96.0 - 109.5
502.5 100.5 91.9 - 109.9
509.1 101.8 95.6 - 108.5
fa – flask ampoule
TABLE I - Mean diameters of the growth inhibition zones 
obtained for the CFTX standard curve for 16, 32 and 64 μg/mL 
solutions
Concentration 
(μg/mL)
Mean diameter ± SDa 
(mm)
RSD 
(%)
16 16.3 +/- 0.3 1.9
32 19.4 +/- 0.2 1.0
64 22.4 +/- 0.5 2.0
a n= 12 independent assays with 6 Petri dishes each
The accuracy of the method was evaluated at 80, 
100 and 120% of the range selected for the bioassay 
(16-64 μg/mL),  covering the specif ic  range of 
12.8-76.8 μg/mL. The mean accuracy was 100.5% with 
an RSD of 1.6% (Table V). Thus, the results obtained in 
the bioassay were close to the true concentration values 
of the tested samples. Moreover, it shows the capacity 
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of the proposed method to accurately quantify or detect 
samples containing low or high concentrations of CFTX, 
displaying that the bioassay is able to detect samples that 
do not meet the assay requirements recommended by the 
Pharmacopeias. Generally, this essential parameter for 
quantitative methods is not tested in agar diffusion assay 
validation studies.
To evaluate the selectivity of the proposed 
method, a CFTX commercial sample reconstituted to 
10 mg/mL was exposed to dry heat (50 ºC) for 48 h. 
The concentration of the remaining CFTX in the sample 
was assessed by both the LC pharmacopeial method 
(United States Pharmacopeia, 2011) and the proposed 
bioassay at 0, 24 and 48 h. At time zero, the CFTX 
potency was 103.1% ± 0.6 and 107.3% ± 0.6 in the 
bioassay and HPLC, respectively. The CFTX showed 
low thermal stability, as shown in Figure 2, in which 
similar decreasing concentration curves were registered 
by both methods. However, the microbiological assay 
presented higher sensitivity, because it showed a decrease 
in potency of approximately 77%, as compared to 53% 
detected by HPLC for the same sample. This preliminary 
result shows that the decomposition products of CFTX 
were not microbiologically active. Therefore, the 
microbiological assay was shown to be specific, because 
the impurities and degradation products did not interfere 
in the ability of the method to assess the analyte.
Figure 3 displays the chromatograms of the CFTX 
sodium reference standard (A), the freshly prepared 
sample (B), and after 24 h (C) and 48 h (D) of exposure to 
dry heat at 50 ºC. The main peak at approximately 3.7 min 
corresponds to CFTX. In 3C and 3D, the secondary peaks 
increase, mainly at approximately 3.5 min. 
Considering the quantitation purpose of this 
bioassay and its inherent response variability that is 
characteristic of all bioassays systems (United States 
Pharmacopeia, 2011), it was considered essential to test the 
influence of small variations in the analytical conditions 
initially proposed. Among several critical factors involved 
in an agar diffusion assay, 4 were selected. These are 
directly related to the substance diffusibility and the 
growth of the inoculum. Therefore, to assess the method 
robustness, the following parameters were modified: 
inoculum concentration (1.3%), incubation temperature 
(32 °C), volume (thickness) of the inoculated layer (4 mL) 
and the solvent used for standard and sample dilution 
(bidistilled water) as shown in Table VI. The results 
showed no significant influence on the mean potencies 
when an ANOVA was applied (P<0.05), supporting the 
robustness of the method. The robustness results were 
also close to the range of 96.2% to 102.8% obtained under 
normal conditions for the repeatability, between-day/
analyst precision and accuracy at 100% of the nominal 
concentration. 
TABLE V - Accuracy of the proposed microbiological assay assessed by the analysis, in triplicate, of CFTX sample solutions diluted 
to 80%, 100% and 120% of the theoretical concentration
Theoretical potency (%) Day Potency found (%) Average potency (%) Accuracy (%) RSD (%)
80
1 81.9
81.8
100.5 1.6
2 81.5
3 81.9
100
1 99.1
99.02 99.3
3 98.5
120
1 120.3
120.42 120.1
3 120.7
FIGURE 2 - Bioassay selectivity: the remaining content of CFTX 
at time 0, 24 and 48 h of exposure to dry heat at 50 ºC as assessed 
by HPLC and the biological assay.
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TABLE VI - Robustness data of the CFTX bioassay validation tested at 100% theoretical sample concentration
Condition challenged Parameter Potency found (%) Confidence interval (IC95) RSD (%)
Inoculum concentration 1.3%
99.3
99.2
100.2
93.7 - 105.4
94.2 - 104.6
93.0 - 107.2
2.3
Incubation temperature 32ºC
101.0
102.7
102.7
94.3 - 108.2
96.3 - 109.6
95.2 - 110.8
Inoculated layer 4 ml
101.4
101.2
101.4
92.3 - 111.5
92.8 - 110.4
97.1 - 105.8
Standard/sample solvent Bidistilled water
95.4
98.9
99.5
86.1 - 105.5
89.9 - 108.8
90.6 - 109.2
FIGURE 3 - Chromatograms of the CFTX reference standard (A). Freshly prepared sample (B). Sample after exposure to dry heat 
at 50 ºC for 24 h (C) and 48 h (D). The CFTX main peak is at 3.7 min. The chromatographic parameters were λ=270-nm, C18 
column and mobile phase (water, acetonitrile, buffer solution pH 7, buffer solution pH 5 – 552:400:44:4) containing 0.32% of 
tetraheptylammonium bromide was used at a flow rate of 2 mL/min.
CONCLUSION
Analytical methods used for the quantitative 
determination of active substances must generate 
reproducible and reliable data. Therefore, in the routine 
quality control of medicine, it is mandatory to use well-
characterized and fully validated analytical methods to 
yield reliable results that can be satisfactorily interpreted. 
The proposed microbiological assay for determining the 
potency of CFTX in pharmaceutical formulations was fully 
validated according to the ICH parameters and produced 
results which confirm its specificity, accuracy, robustness, 
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precision and significant linearity of response. Moreover, 
the bioassay produced results supporting those obtained 
by the pharmacopeial LC method for CFTX. However, 
the biological method has several advantages, including 
its simplicity and low cost, becoming increasingly 
appropriate when a LC system is not available for 
determining the potency of the antibiotic. Therefore, the 
proposed bioassay can be a useful method in the quality 
control of ceftriaxone sodium in pharmaceutical products 
and the raw material.
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